Amniotics

About:

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid.

Website: https://www.amniotics.com/

Top Investors: Almi Invest, LU Innovation

Description:

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (MPA in Sweden), approved GMP (Good Manufacturing Practice) manufacturing facility to produce Advanced therapy medicinal products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Total Funding Amount:

20M SEK

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Lund, Skane Lan, Sweden

Founded Date:

2015-01-01

Contact Email:

info(AT)amniotics.com

Founders:

Marcus Larsson

Number of Employees:

1-10

Last Funding Date:

2021-01-12

IPO Status:

Public

Industries:

© 2025 bioDAO.ai